Clinical Trial Detail

NCT ID NCT02939807
Title A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors RedHill Biopharma Limited
Indications

hepatocellular carcinoma

Therapies

ABC294640

Age Groups: adult senior

No variant requirements are available.